Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cellectar Biosciences, Inc.

NASDAQ: CLRB · Life Sciences · 2 alerts · CIK 1279704

Share price
$1.01Close, Nov 16
Market cap
$10.1M
Shares outstanding
10.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cellectar Biosciences, Inc. filings on SEC EDGAR ↗

7:25 AM ET 8-K
Financial Results

Cellectar Biosciences Financial Results

Cellectar Biosciences reported financial results for the third quarter of 2026, highlighting progress toward a planned accelerated approval filing for iopofosine I 131 in Waldenström macroglobulinemia (WM). The company remains on track to file its NDA with the FDA in the first half of 2027 and expects to dose the first patients in its Phase 3 confirmatory trial in Q1 2027.

Term
Q3 2026

“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal.”

James Caruso, president and chief executive officer of Cellectar Biosciences

“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line.”

James Caruso, president and chief executive officer of Cellectar Biosciences
6:56 AM ET 10-Q
Financial Results

Cellectar Biosciences Q3 2026 Results: Net Loss of $7.97M, Loss Widens

Cellectar Biosciences reported a net loss of $20.6 million for the nine months ended September 30, 2026, as it continues to invest in its phospholipid drug conjugate platform. The company significantly improved its cash position to $24.6 million through the issuance of common stock and warrants, though management notes a continued dependence on outside capital to fund operations.

Key figure
Net loss $7.97M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.